Onyvax is developing new cancer therapies that harness the selective
power of the immune system to seek out and destroy tumor cells.
Onyvax's products specifically target cancer cells, increasing the
likelihood that they will be effective while minimising side effects
associated with many conventional treatments. These therapies can
broadly be classed as therapeutic cancer vaccines.
Onyvax's lead product is in clinical trials for the treatment
of prostate cancer and is poised to enter the final stages of
development.
Onyvax is committed to the commercialisation of novel therapies
that enhance survival while maintaining a high quality of life
for patients. The Company is based in London and has collaborations
with leading hospitals and other institutions throughout Europe
and the US.
